MedTrace Logo

Antibody Titer Analysis After H1N1 Vaccination in Pediatric Haemato-oncology Patients

NCT01046227 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2010-01-11

No results posted yet for this study

Summary

The patients of pediatric haemato-oncology have a higher risk for novel H1N1 influenza infection than general population, and they are strongly recommended to receive novel H1N1 vaccination. However, there is no previous data to answer how the efficacy and effectiveness of novel H1N1 vaccination is in patients of pediatric haemato-oncology. This study is designed to investigate the antibodies titers before and after the novel H1N1 influenza vaccination in these patients. Titer of H1N1 influenza virus antibodies will be determined by hemagglutinin inhibition assay (HAI). A HAI titer with a 4-fold rise or greater is defined as seroconversion. Study subjects with seroconversion are regarded as responsiveness to the vaccination. Meanwhile, if the patient presents influenza-like symptoms, we will perform throat swab or nasal swab for influenza rapid test, viral isolation, and novel H1N1 influenza PCR to confirm the diagnosis. After the study, we will be able to know whether or not current novel H1N1 influenza vaccination schedule is adequate and efficient for pediatric haemato-oncology patients.

Conditions

  • Serology Analysis
  • Novel H1N1 Influenza Vaccination
  • Pediatric Haemato-oncology Patients

Interventions

BIOLOGICAL

Influenza A (H1N1) 2009 monovalent vaccine, inactivated

Serology study before and after Influenza A (2009) monovalent vaccine, inactivated

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Luan-Yin Chang, MD · National Taiwan University Hospital, Taipei, Taiwan

Eligibility

Min Age
6 Months
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-02-28
Completion
2010-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01046227 on ClinicalTrials.gov